Glaxo, Vir Biotech initiates of NIH-sponsored VIR-7831 study in COVID-19

 

• Vir Biotechnology (NASDAQ:VIR) and GlaxoSmithKline (NYSE:GSK) have announced dosing of the first patient in a new sub-trial of the National Institutes of Health’s (NIH) ACTIV Program Phase 3 trial, evaluating VIR-7831 (a.k.a GSK4182136) for the treatment of hospitalized adults with COVID-19.
• The study will assess safety and efficacy of the monoclonal antibody.
• ACTIV-3 is one of several ongoing trials in the NIH’s ACTIV program, a public-private partnership designed to accelerate development of COVID-19 treatments and vaccine candidates.
• In addition to the Phase 3 ACTIV-3 trial, VIR-7831 is also being evaluated in the global Phase 2/3 COMET-ICE trial for the early treatment of COVID-19 in adults at high risk of hospitalization.
• https://seekingalpha.com/news/3645499-gsk-vir-biotech-initiates-of-nih-sponsored-virminus-7831-study-in-covidminus-19